Summary

Eligibility
for people ages 2 months and up (full criteria)
Location
at UC Davis UCSD
Dates
study started
study ends around

Description

Summary

The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.

Official Title

Eliminating Monitor Overuse (EMO) Hybrid Effectiveness-Deimplementation Trial

Keywords

Bronchiolitis Acute Viral, pulse oximetry, deimplementation, cluster-randomized trial, effectiveness-implementation hybrid trial, implementation science, Educational Outreach, Audit & Feedback (unit level), Audit & Feedback (real time, individual-level), Clinical Pathway Integrated into Electronic Health Record, Unlearning + Substitution

Eligibility

For people ages 2 months and up

Population a: Bronchiolitis patients directly observed while not receiving supplemental oxygen ("in room air," for primary trial outcome)

Inclusion Criteria:

  • Infants and children 2 months through 23 months old
  • Hospitalized on non-ICU wards participating in the trial
  • Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)
  • Primary diagnosis of bronchiolitis in most recent physician progress note
  • Not actively receiving supplemental oxygen ("in room air")
  • Last documented receipt of supplemental oxygen >1 hour prior to direct observational data collection

Exclusion Criteria:

Population b: Bronchiolitis patients directly observed while receiving supplemental oxygen (for underuse evaluation).

Inclusion Criteria:

  • Infants and children 2 months through 23 months old
  • Hospitalized on non-ICU wards participating in the trial
  • Cared for by generalist inpatient services (e.g. general pediatrics, hospital medicine)
  • Primary diagnosis of bronchiolitis in most recent physician progress note
  • Actively receiving ≥2 Liters/minute (2L/min) supplemental oxygen or 21% room air flow

Exclusion Criteria:

  • Extreme prematurity (<28 weeks completed gestation)
  • Cardiac disease
  • Pulmonary hypertension
  • Chronic lung disease
  • Home oxygen requirement
  • Neuromuscular disease
  • Immunodeficiency
  • Cancer
  • Severe Acute Respiratory Syndrome Coronavirus 2 [Covid-19 / SARS-CoV-2 (known or suspected)]

Locations

  • University of California Davis
    Davis California 95616 United States
  • Rady Children's Hospital/UCSD
    Encinitas California 92024 United States
  • Children's Hospital Los Angeles
    Los Angeles California 90027 United States
  • Children's Hospital Orange County
    Orange California 92868 United States
  • Valley Children's Hospital
    Madera California 93636 United States
  • Lucile Packard Children's Hospital Stanford
    Stanford California 94304 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Hospital of Philadelphia
ID
NCT05132322
Study Type
Interventional
Participants
About 9265 people participating
Last Updated